Generic placeholder image

Recent Patents on Medical Imaging


ISSN (Print): 2210-6847
ISSN (Online): 1877-6132

Positron Emission Tomography for Future Drug Development

Author(s): Ryogo Minamimoto, Chumpol Theeraladanon, Akiko Suzuki and Tomio Inoue

Volume 1, Issue 2, 2011

Page: [137 - 151] Pages: 15

DOI: 10.2174/1877613211101020137

Price: $65


Productivity in the drug discovery and development process has seen a drastic decline over the last few years. Clearly, traditional approaches to drug development are not working. The new concept called “microdosing studies” was recently announced as a promising methodology for accreting drug development. The microdosing studies is a concept by administrating a low dose (microdose) of a candidate compound to human volunteers to obtain in vivo human pharmacokinetic (PK) data at an early stage of drug development. As a result unpromising candidate drugs can be eliminated at an earlier stage of drug development. A key component for this concept is highly sensitive analytical methods such as positron emission tomography (PET), accelerator mass spectrometry (AMS) and liquid chromatography-mass spectrometry (LC/MS/MS). This issue focuses on PET methodology from basic to future prospects for drug development and patents related to it.

Keywords: Positron emission tomography (PET), PET/CT, drug development, microdosing, imaging, microdosing approach, primary pharmacodynamics, conventional clinical trials, accelerator mass spectrometry, liquid chromatography-mass spectrometry, non-invasive imaging, in vivo human pharmacokinetic, proton-rich isotopes, line of response, radiopharmaceutical sciences

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy